{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T21:51:26Z","timestamp":1777758686939,"version":"3.51.4"},"reference-count":154,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a systemic autoimmune inflammatory disease affecting both the joints and the skin, with the potential involvement of multiple organ systems. A hallmark feature of PsA is enthesitis\u2014inflammation at the sites where tendons and ligaments insert into bone\u2014which arises from a combination of mechanical stress and immune-mediated inflammation. Another defining characteristic of the disease is the paradoxical coexistence of bone erosion and new bone formation, distinguishing it from other inflammatory arthritides. The therapeutic landscape of PsA has evolved considerably over time. Non-steroidal anti-inflammatory drugs (NSAIDs) remain a cornerstone of symptom management, while conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate, are widely used to control disease progression. The introduction of biologic agents has revolutionized PsA management, with TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors demonstrating efficacy across a broad range of clinical manifestations. More recently, targeted synthetic small molecules\u2014including JAK inhibitors and TYK2 inhibitors\u2014have expanded the armamentarium of available therapies. The overarching goals of treatment in PsA include the suppression of the underlying inflammatory process and the prevention of structural joint damage. The impact of each therapeutic option on cutaneous psoriasis is an additional and important consideration that guides individualized treatment options.<\/jats:p>","DOI":"10.3390\/life16050740","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:31:56Z","timestamp":1777465916000},"page":"740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies\u2014A Scoping Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Lambros","family":"Athanassiou","sequence":"first","affiliation":[{"name":"Department of Rheumatology, St. Paul\u2019s Hospital, 55134 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2029-8372","authenticated-orcid":false,"given":"Ifigenia","family":"Kostoglou-Athanassiou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Asclepeion Hospital, Voula, 16673 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kaiafa","sequence":"additional","affiliation":[{"name":"First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Savopoulos","sequence":"additional","affiliation":[{"name":"First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[{"name":"Medical School, Reichman University, Herzliya 4610101, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-7394","authenticated-orcid":false,"given":"Panagiotis","family":"Athanassiou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St. Paul\u2019s Hospital, 55134 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref_1","first-page":"65","article-title":"Psoriatic arthritis: State of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin. Med. J. R. Coll. Physicians Lond."},{"key":"ref_2","first-page":"40","article-title":"Psoriatic arthritis","volume":"159","author":"Laiz","year":"2022","journal-title":"Med. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/1346-8138.15954","article-title":"Psoriatic arthritis","volume":"48","author":"Umezawa","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"I21","DOI":"10.1093\/rheumatology\/keaa042","article-title":"Enthesitis in psoriatic arthritis (part 3): Clinical assessment and management","volume":"59","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo","year":"2019","journal-title":"F1000Research"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.7150\/ijbs.90677","article-title":"The FTO-CMPK2 Pathway in Fibroblast-like Synoviocytes Modulates Rheumatoid Arthritis Synovial Inflammation and Cartilage Homeostasis via mtDNA Regulation","volume":"20","author":"Jin","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"ref_8","first-page":"36","article-title":"Osteoporosis and psoriatic arthritis","volume":"39","author":"Esposito","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ncprheum0670","article-title":"Psoriatic disease\u2014From skin to bone","volume":"3","author":"Ritchlin","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zalesak, M., Danisovic, L., and Harsanyi, S. (2024). Psoriasis and Psoriatic Arthritis\u2014Associated Genes, Cytokines, and Human Leukocyte Antigens. Medicina, 60.","DOI":"10.3390\/medicina60050815"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s10067-016-3295-9","article-title":"Psoriatic arthritis and psoriasis: Differential diagnosis","volume":"35","author":"Napolitano","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaad.2024.03.059","article-title":"Psoriatic arthritis: A comprehensive review for the dermatologist part I: Epidemiology, comorbidities, pathogenesis, and diagnosis","volume":"92","author":"Elman","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Azuaga, A.B., Ram\u00edrez, J., and Ca\u00f1ete, J.D. (2023). Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054901"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ii74","DOI":"10.1136\/ard.2004.030783","article-title":"Psoriatic arthritis therapy: NSAIDs and traditional DMARDs","volume":"64","author":"Nash","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/rheumatology\/keaa526","article-title":"Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope","volume":"60","author":"Tillett","year":"2021","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104473","DOI":"10.1016\/j.phrs.2019.104473","article-title":"Biological and synthetic target DMARDs in psoriatic arthritis","volume":"149","author":"Silvagni","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yi, R.C., Akbik, M., Smith, L.R., Klionsky, Y., and Feldman, S.R. (2025). Therapeutic Advancements in Psoriasis and Psoriatic Arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041312"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zeng, J., Lin, L., Li, W., Gao, X., Li, Q., Zhou, X., Liu, W., Zhong, X., Yang, Y., and Zhang, X. (2025). Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1669786"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70130","DOI":"10.1111\/1756-185X.70130","article-title":"The Safety and Efficacy of JAK Inhibitors: Have We Found the Right Pathway?","volume":"28","author":"Wang","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/14656560802653198","article-title":"Treatment strategies for early psoriatic arthritis","volume":"10","author":"Olivieri","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/187152811304140915152102","article-title":"An update on disease modifying antirheumatic drugs","volume":"13","author":"Joshi","year":"2014","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14740338.2021.1965988","article-title":"Gastrointestinal and cardiovascular adverse events associated with NSAIDs","volume":"21","author":"Lanas","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/14712598.8.3.363","article-title":"Adalimumab for the treatment of severe psoriasis and psoriatic arthritis","volume":"8","author":"Papoutsaki","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of Therapeutic Drug Monitoring vs Standard Therapy during Maintenance Infliximab Therapy on Disease Control in Patients with Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"ref_29","first-page":"S116","article-title":"Psoriatic arthritis: The role of TNF inhibition and the effect of its inhibition with etanercept","volume":"20","author":"Mease","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/14712598.3.1.169","article-title":"Etanercept in psoriatic arthritis","volume":"3","author":"Anandarajah","year":"2003","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/157488706778250131","article-title":"Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis","volume":"1","author":"Fuchs","year":"2008","journal-title":"Rev. Recent Clin. Trials"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00128071-200708030-00002","article-title":"Efficacy and safety of etanercept in psoriasis\/psoriatic arthritis: An updated review","volume":"8","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Logiudice","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","article-title":"Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs","volume":"29","author":"Atteno","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chen, Y.F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., and Burls, A. (2006). A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess., 10.","DOI":"10.3310\/hta10420"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3310\/hta15100","article-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: A systematic review and economic evaluation","volume":"15","author":"Rodgers","year":"2011","journal-title":"Health Technol. Assess."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Woolacott, N., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K., Light, K., Asseburg, C., Palmer, S., and Claxton, K. (2006). Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation. Health Technol. Assess., 10.","DOI":"10.3310\/hta10310"},{"key":"ref_38","first-page":"S15","article-title":"Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis","volume":"21","author":"Bongiorno","year":"2008","journal-title":"Dermatol. Ther."},{"key":"ref_39","first-page":"77","article-title":"Adalimumab in psoriatic arthritis","volume":"89","author":"Salvarani","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zou, H., Li, R., Hu, H., Hu, Y., and Chen, X. (2018). Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00594"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"McIntosh, S.M., Kerut, C., Hollenshead, P.P., Askins, D.H., Mansourian, K., Palowsky, Z.R., Allampalli, V., Ahmadzadeh, S., Shekoohi, S., and Kaye, A.D. (2023). Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations. Life, 13.","DOI":"10.3390\/life13071601"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","article-title":"Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: Results from the RAPID-PsA randomized controlled trial","volume":"37","author":"Walsh","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/1744666X.2020.1713754","article-title":"Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis","volume":"16","author":"Esposito","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/rheumatology\/keaa271","article-title":"Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis","volume":"60","author":"Coates","year":"2021","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13075-020-2126-1","article-title":"Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: Results from a phase-3, double-blind, placebo-controlled trial","volume":"22","author":"Mease","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2012-202035","article-title":"Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"A386","DOI":"10.1016\/j.jval.2014.08.2646","article-title":"Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis with Certolizumab Pegol: 96-Week Patient-Reported Outcome Results of the Rapid-Psa Study","volume":"17","author":"Gladman","year":"2014","journal-title":"Value Health"},{"key":"ref_53","first-page":"375","article-title":"The Overview of the Immunobiology of Interleukin-23 Associated with Immune-Mediated Inflammatory Disorders: A Narrative Review","volume":"22","author":"Sanchez","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14712598.2021.1938538","article-title":"IL-23 inhibition for the treatment of psoriatic arthritis","volume":"22","author":"Mohanakrishnan","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2018.09.002","article-title":"Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight","volume":"206","author":"Nguyen","year":"2019","journal-title":"Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Vecellio, M., Hake, V.X., Davidson, C., Carena, M.C., Wordsworth, B.P., and Selmi, C. (2021). The IL-17\/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.596086"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","article-title":"Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis","volume":"34","author":"Raychaudhuri","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_58","first-page":"115","article-title":"Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis","volume":"33","author":"Johnsson","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"I10","DOI":"10.1093\/rheumatology\/keaa039","article-title":"Enthesitis in psoriatic arthritis (Part 1): Pathophysiology","volume":"59","author":"Araujo","year":"2020","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"IV4","DOI":"10.1093\/rheumatology\/keab266","article-title":"IL-23 orchestrating immune cell activation in arthritis","volume":"60","author":"Najm","year":"2021","journal-title":"Rheumatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","article-title":"Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study","volume":"20","author":"Coates","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: Results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sundanum, S., Orr, C., and Veale, D. (2023). Targeted Therapies in Psoriatic Arthritis\u2014An Update. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076384"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.2147\/JIR.S229752","article-title":"Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection","volume":"14","author":"Miller","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/imt-2020-0225","article-title":"Ixekizumab in the treatment of psoriatic arthritis","volume":"13","author":"Lespessailles","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/imt-2023-0240","article-title":"Bimekizumab for The Treatment of Psoriasis","volume":"16","author":"Thapar","year":"2024","journal-title":"Immunotherapy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40744-024-00652-7","article-title":"Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gao, S., Xie, X., Fan, L., and Yu, L. (2025). Efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors for psoriatic arthritis: A network meta-analysis of randomized controlled trials. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1654343"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14712598.2019.1579794","article-title":"Brodalumab for the treatment of plaque psoriasis: Up-to-date","volume":"19","author":"Beck","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, ixekizumab, bimekizumab and brodalumab for the treatment of psoriasis and psoriatic arthritis","volume":"59","author":"Simopoulou","year":"2023","journal-title":"Drugs Today"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1038\/s41591-025-03971-6","article-title":"Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled phase 2 trial","volume":"31","author":"McInnes","year":"2025","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1080\/09546634.2022.2062281","article-title":"The dark side of the moon: The immune-mediated adverse events of IL-17A\/IL-17R inhibition","volume":"33","author":"Messina","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40257-025-00928-w","article-title":"Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review","volume":"26","author":"Kim","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Aggarwal, P., and Fleischer, A.B. (2024). IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175139"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/rheumatology\/keac500","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: Updates to a systematic literature review and network meta-analysis","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kead705","article-title":"Comparative efficacy and safety of bimekizumab in psoriatic arthritis: A systematic literature review and network meta-analysis","volume":"63","author":"Mease","year":"2024","journal-title":"Rheumatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Papp","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40744-024-00638-5","article-title":"Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Su","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-013-0025-6","article-title":"Therapeutic strategies in psoriasis patients with psoriatic arthritis: Focus on new agents","volume":"27","author":"Gan","year":"2013","journal-title":"BioDrugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/ijd.16849","article-title":"Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas","volume":"62","author":"Vaiopoulos","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: A meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10067-025-07368-1","article-title":"Sequential biologic therapy in the treatment of active psoriatic arthritis in China: A cost-effectiveness analysis","volume":"44","author":"Xie","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e000990","DOI":"10.1136\/rmdopen-2019-000990","article-title":"Efficacy of ustekinumab in biologic-na\u00efve patients with psoriatic arthritis by prior treatment exposure and disease duration: Data from PSUMMIT 1 and PSUMMIT 2","volume":"5","author":"McInnes","year":"2019","journal-title":"RMD Open"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e001600","DOI":"10.1136\/rmdopen-2021-001600","article-title":"Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study","volume":"7","author":"Mease","year":"2021","journal-title":"RMD Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1759720X231189005","DOI":"10.1177\/1759720X231189005","article-title":"The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2","volume":"15","author":"Deodhar","year":"2023","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40744-025-00748-8","article-title":"Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials","volume":"12","author":"Kristensen","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/25785826.2023.2172808","article-title":"JAK inhibitors in rheumatology","volume":"46","author":"Yamaoka","year":"2023","journal-title":"Immunol. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/25785826.2023.2183594","article-title":"JAK inhibitors \u223c overview\u223c","volume":"46","author":"Kameda","year":"2023","journal-title":"Immunol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"103276","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10067-024-06940-5","article-title":"Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Dai","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"172","DOI":"10.25259\/IJDVL_14_2024","article-title":"Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials","volume":"91","author":"Wang","year":"2025","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.23736\/S0392-0488.20.06643-2","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"155","author":"Ighani","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/imt-2017-0087","article-title":"Tofacitinib in psoriatic arthritis","volume":"9","author":"Wang","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_117","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","article-title":"Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated with Disease Activity, Pharmacodynamics, and Clinical Responses","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Martins, A., L\u00e9, A.M., and Torres, T. (2023). Deucravacitinib for the treatment of psoriatic arthritis: The evidence so far. Drugs Context, 12.","DOI":"10.7573\/dic.2023-2-7"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: A phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and Safety of the TYK2\/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","article-title":"Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease","volume":"42","author":"Burmester","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"106359","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"66","DOI":"10.31138\/mjr.040123.sot","article-title":"State of the Art Review on the Treatment of Psoriatic Disease","volume":"35","author":"Pelechas","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_127","first-page":"411","article-title":"New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis","volume":"155","author":"Chiricozzi","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_128","first-page":"2286","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study","volume":"41","author":"Mease","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s13555-025-01428-9","article-title":"Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms","volume":"15","author":"Merola","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"386","DOI":"10.23736\/S0392-0488.20.06640-7","article-title":"Apremilast and its role in psoriatic arthritis","volume":"155","author":"Sandhu","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis","volume":"15","author":"Metyas","year":"2018","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-014-0005-4","article-title":"Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis","volume":"1","author":"Mease","year":"2014","journal-title":"Rheumatol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1759720X16673786","article-title":"Apremilast in the treatment of psoriatic arthritis: A perspective review","volume":"9","author":"Reed","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Jugder, B.E., Park, E., Du, L., Jawale, C., Popov, N., Guo, Z., Bednar, K.J., and Ort, T. (2025). Tissue-specific roles of regulatory T cells: Mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1650451"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Shi, Y., Wang, L., Bao, C., Wang, G., and Sun, Z. (2026). Tissue-resident regulatory T cells: Modulators of local immunity. Trends Immunol.","DOI":"10.1016\/j.it.2025.12.001"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Queiro, R., Alonso, S., and Alperi, M. (2026). Beyond cytokine blockade: Could CAR-Tregs open a new era of tissue-targeted immune tolerance in psoriatic arthritis?. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1772369"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/07315724.2002.10719248","article-title":"Omega-3 fatty acids in inflammation and autoimmune diseases","volume":"21","author":"Simopoulos","year":"2002","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.plefa.2018.03.004","article-title":"Omega-6 fatty acids and inflammation","volume":"132","author":"Innes","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: From molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"116744","DOI":"10.1016\/j.lfs.2019.116744","article-title":"Vitamin D and autoimmune diseases","volume":"233","author":"Ruiz","year":"2019","journal-title":"Life Sci."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"S\u00eerbe, C., Rednic, S., Grama, A., and Pop, T.L. (2022). An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179784"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"152200","DOI":"10.1016\/j.semarthrit.2023.152200","article-title":"Vitamin D in psoriatic arthritis\u2014A systematic review and meta-analysis","volume":"60","author":"Kolak","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_145","first-page":"e81086","article-title":"Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review","volume":"17","author":"Leiber","year":"2025","journal-title":"Cureus"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1759720X241271886","DOI":"10.1177\/1759720X241271886","article-title":"Metabolic syndrome and psoriatic arthritis: The role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/1744666X.2020.1740593","article-title":"Metabolic Syndrome and psoriatic arthritis: Considerations for the clinician","volume":"16","author":"Caso","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/OARRR.S347797","article-title":"Metabolic Syndrome and Its Components in Psoriatic Arthritis","volume":"14","author":"Aljohani","year":"2022","journal-title":"Open Access Rheumatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/AAP.0000000000000218","article-title":"Obesity and chronic pain: Systematic review of prevalence and implications for pain practice","volume":"40","author":"Narouze","year":"2015","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e005717","DOI":"10.1136\/rmdopen-2025-005717","article-title":"Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: Another mosaic tile in the definition of a still undefined subset of patients","volume":"11","author":"Currado","year":"2025","journal-title":"RMD Open"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-019-1938-3","article-title":"Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.12.9.1085","article-title":"Targeting tumor necrosis factor \u03b1 in psoriasis and psoriatic arthritis","volume":"12","author":"Fantuzzi","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/rheumatology\/keab315","article-title":"Apremilast inhibits inflammatory osteoclastogenesis","volume":"61","author":"Degboe","year":"2021","journal-title":"Rheumatology"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:12:01Z","timestamp":1777468321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":154,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["life16050740"],"URL":"https:\/\/doi.org\/10.3390\/life16050740","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}